Our health care roundtable gathers the Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.
In this portion of the discussion, the Fool's health care team tackles the recent big pharma trend of spinning off whole divisions, like Abbott Labs' (ABT 0.03%) plans for pharmaceutical-focused AbbVie. Would conglomerate Johnson & Johnson (JNJ +2.22%) benefit from shedding a little extra weight and spinning off a company or two?
